Paper Review Records
All Paper Review Records
18 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
109
days
YAP Signaling in Cutaneous Melanoma Therapy Resistance: Immune Remodeling, Adaptive Reprogramming, and Therapeutic Challenges
Authors
Tian Zhao; Shiwei Zhang; Ruxin Xie; Chenyu Li; Zhaosen Zhou; Junjie ChenShow moreShow less
Affiliations
1. Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu, P. R. ChinaShow moreShow less
52
days
Precision Adjuvant Therapy in Gastrointestinal Stromal Tumor: Adjuvant-Specific Evidence Versus Metastatic Extrapolation
Authors
Wen-Kuan Huang; Shang-Yu Wang; Chun-Nan YehShow moreShow less
Affiliations
1. Division of Hematology-Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; 2. College of Medicine, Chang Gung University, Taoyuan, Taiwan; 3. Division of General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan; 4. National Tsing Hua University, Hsinchu, TaiwanShow moreShow less
15
days
Radiotherapy for Adult-Type Diffuse WHO Grade 2 Gliomas in the Era of IDH Inhibition: A Narrative Review
Authors
Alper Kahvecioglu; Gozde YaziciShow moreShow less
Affiliations
1. Department of Radiation Oncology, Hacettepe University, Ankara, TurkeyShow moreShow less
232
days
Synergizing Short-Course Radiotherapy with Immunotherapy in Locally Advanced Rectal Cancer: Current Evidence, Challenges, and Future Directions
Authors
Lemeng Xu; Ye Jiao; Yongchang Wei; Min LuoShow moreShow less
Affiliations
1. Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China; 2. Department of Oncology and Hematology, Tongshan County People’s Hospital, Xianning, ChinaShow moreShow less
29
days
Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities
Authors
Huanxin Yan; Xiaoli ShiShow moreShow less
Affiliations
1. Department of Pharmacy, the Affiliated Hospital of Qingdao University, Qingdao, ChinaShow moreShow less
208
days
Personalized Therapy with Mercaptopurine in Acute Lymphoblastic Leukemia: Current Advances and Challenges
Authors
Haoping He; Bowei Chen; Xiaoqiang Hao; Haoyue Li; Jia Du; Weiwei Liu; Aijun ZhangShow moreShow less
Affiliations
1. Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China; 2. School of Basic Medical Sciences of Shandong University, Jinan, ChinaShow moreShow less
FAQ
How long does CURRENT TREATMENT OPTIONS IN ONCOLOGY take to review a manuscript?
As of 2026-11-18, CrushSCI has 18 complete review records for CURRENT TREATMENT OPTIONS IN ONCOLOGY. The fastest paper went from submission to acceptance in 12 days (Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach, received 2026-07-24, accepted 2026-08-05); the slowest took 232 days. The average is 76.2 days and the median is 48.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
